Get the Stockscreener App
39.73
0.89%
0.35
Xenon Pharmaceuticals Inc stock is traded at $39.73, with a volume of 230.32K.
It is up +0.89% in the last 24 hours and up +1.92% over the past month.
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.
See More
Previous Close:
$39.38
Open:
$39.96
24h Volume:
230.32K
Relative Volume:
0.59
Market Cap:
$3.03B
Revenue:
$13.17M
Net Income/Loss:
$-199.06M
P/E Ratio:
-14.50
EPS:
-2.74
Net Cash Flow:
$-156.53M
1W Performance:
+2.11%
1M Performance:
+1.92%
6M Performance:
+1.51%
1Y Performance:
-18.64%
1-Day Range:
$39.32
$40.00
1-Week Range:
$37.68
$40.00
52-Week Range:
$35.53
$50.99
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Name
Xenon Pharmaceuticals Inc
Sector
Industry
Phone
(604) 484-3300
Address
200 - 3650 GILMORE WAY, BURNABY
Compare XENE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
39.73 | 3.03B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jan-04-24 | Initiated | Citigroup | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-25-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-14-22 | Initiated | Goldman | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Oct-19-22 | Initiated | Raymond James | Outperform |
| Aug-29-22 | Initiated | BofA Securities | Buy |
| Jul-21-22 | Initiated | JP Morgan | Overweight |
| Oct-28-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Jul-21-20 | Initiated | Needham | Buy |
| Jun-01-20 | Resumed | Jefferies | Buy |
| Mar-25-20 | Initiated | Wedbush | Outperform |
| Jan-08-20 | Initiated | William Blair | Outperform |
| Sep-20-19 | Initiated | Guggenheim | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Mar-13-17 | Initiated | Jefferies | Buy |
| Oct-21-16 | Initiated | Stifel | Buy |
| Sep-26-16 | Initiated | Guggenheim | Buy |
| Apr-14-16 | Reiterated | Jefferies | Buy |
| Oct-30-15 | Resumed | Jefferies | Buy |
| Dec-02-14 | Initiated | Canaccord Genuity | Buy |
View All
Xenon Pharmaceuticals Inc Stock (XENE) Latest News
Xenon Pharmaceuticals (XENE) Projected to Post Earnings on Thursday - Defense World
TimesSquare Capital Management LLC Boosts Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals CEO sells shares worth $2.21 million - MSN
Xenon Pharmaceuticals to Announce Q4 and Full Year 2024 Financial Results - TipRanks
Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025 - The Manila Times
Can Xenon's Promising Epilepsy Drug Pipeline Deliver? Q4 Results Will Tell - StockTitan
Epilepsy Market Assessment in the 7MM by 2034 — A Detailed Analysis of Growth Prospects Across Different Types | DelveInsight - GlobeNewswire Inc.
(XENE) Trading Advice - Stock Traders Daily
Traders Purchase Large Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE) - Armenian Reporter
Investors Purchase High Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE) - Defense World
Deutsche Bank Aktiengesellschaft Begins Coverage on Xenon Pharmaceuticals (NASDAQ:XENE) - MarketBeat
Analysts Set Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Price Target at $56.00 - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Coverage Initiated at Deutsche Bank Aktiengesellschaft - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives $56.00 Average Target Price from Analysts - Defense World
abrdn plc Boosts Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Deutsche Bank Initiates Coverage of Xenon Pharmaceuticals (XENE) with Buy Recommendation - Nasdaq
XENE stock rated an Outperform by Raymond James - Knox Daily
Deutsche Bank Initiates Coverage on Xenon Pharmaceuticals With Buy Rating, $67 Price Target - Marketscreener.com
(XENE) Trading Signals - Stock Traders Daily
Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Purchased by Jennison Associates LLC - MarketBeat
Blue Trust Inc. Raises Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:XENE) - Defense World
FY2025 EPS Estimate for Xenon Pharmaceuticals Cut by Analyst - MarketBeat
SG Americas Securities LLC Buys 5,577 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Leerink Partnrs Has Bearish Outlook for XENE FY2025 Earnings - Defense World
Learn to Evaluate (XENE) using the Charts - Stock Traders Daily
2,569 Shares in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Acquired by Avior Wealth Management LLC - Defense World
Ian Mortimer Sells 22,468 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock - MarketBeat
Wedbush Lowers Earnings Estimates for Xenon Pharmaceuticals - Defense World
Q1 EPS Estimates for Xenon Pharmaceuticals Cut by Wedbush - MarketBeat
FY2029 Earnings Forecast for XENE Issued By Wedbush - Defense World
Cantor Fitzgerald Predicts XENE FY2025 Earnings - Defense World
Cantor Fitzgerald Estimates XENE FY2025 Earnings - MarketBeat
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - Defense World
Traders Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - MarketBeat
Epidemic Keratoconjunctivitis Market Expected to Reach Huge - openPR
Xenon Pharmaceuticals announces executive changes - MSN
Assenagon Asset Management S.A. Has $9.35 Million Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Assenagon Asset Management S.A. Increases Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
How To Trade (XENE) - Stock Traders Daily
Xenon Pharmaceuticals announces executive changes By Investing.com - Investing.com Australia
Xenon Pharmaceuticals’ CCO Departure and Consultancy Role - MSN
Xenon Pharmaceuticals Inc Stock (XENE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Xenon Pharmaceuticals Inc Stock (XENE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MORTIMER IAN | PRESIDENT & CEO |
Jan 27 '25 |
Option Exercise |
17.76 |
16,315 |
289,754 |
46,468 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 23 '25 |
Option Exercise |
17.76 |
16,217 |
288,014 |
47,519 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 24 '25 |
Sale |
40.20 |
22,468 |
903,214 |
31,302 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 27 '25 |
Sale |
40.50 |
16,315 |
660,806 |
31,302 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 23 '25 |
Sale |
40.08 |
16,217 |
649,977 |
31,302 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):